OSSFF (Embla Medical hf) Additional Paid-In Capital: $85.5 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSSFF Embla Medical hf OSSFF
87 GF Score
Price $4.53
GF Value $5.26
Valuation Modestly Undervalued
View Full Analysis

What is Embla Medical hf Additional Paid-In Capital?

Embla Medical hf OSSFF -0.55% 87 Additional Paid-In Capital is $85.5 Mil as of Jun. 2026. GuruFocus rates OSSFF with a GF Score™ of 87/100 and a GF Value™ of $5.26 (Modestly Undervalued).


Embla Medical hf's quarterly additional paid-in capital declined from Dec. 2025 ($93.6 Mil) to Mar. 2026 ($91.0 Mil) but then stayed the same from Mar. 2026 ($91.0 Mil) to Jun. 2026 ($85.5 Mil).

Embla Medical hf's annual additional paid-in capital increased from Dec. 2023 ($61.5 Mil) to Dec. 2024 ($88.6 Mil) and increased from Dec. 2024 ($88.6 Mil) to Dec. 2025 ($93.6 Mil).

Embla Medical hf Additional Paid-In Capital Related Terms

Embla Medical hf Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Embla Medical hf's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Embla Medical hf Additional Paid-In Capital Chart

Embla Medical hf Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.78 61.43 61.48 88.64 93.63

Embla Medical hf Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 84.36 96.25 93.63 91.02 85.50
OSSFF
87GF Score
Embla Medical hf OSSFF
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Embla Medical hf Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $85.5 Mil mean?
Embla Medical hf (OSSFF) has a Additional Paid-In Capital of $85.5 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Embla Medical hf and its competitors.
Is Embla Medical hf's Additional Paid-In Capital too high?
Embla Medical hf's current Additional Paid-In Capital is $85.5 Mil. Overall, Embla Medical hf has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Embla Medical hf's Additional Paid-In Capital compare to ABT and SYK?
Embla Medical hf's Additional Paid-In Capital of $85.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Medical Devices & Instruments company?
A good Additional Paid-In Capital depends on the Medical Devices & Instruments industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Embla Medical hf and its competitors. Embla Medical hf's current Additional Paid-In Capital is $85.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Embla Medical hf stock overvalued right now?
Based on GuruFocus' analysis, Embla Medical hf (OSSFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $5.26, compared to a current price of $4.53 — trading 14% below its estimated fair value. The current Additional Paid-In Capital is $85.5 Mil. Embla Medical hf's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Embla Medical hf (OSSFF), the current Additional Paid-In Capital is $85.5 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Embla Medical hf (OSSFF) Overvalued in 2026?

Based on GuruFocus' analysis, Embla Medical hf stock appears to be undervalued. The current stock price of $4.53 is trading 14% below its estimated GF Value™ of $5.26. GuruFocus considers Embla Medical hf to be Modestly Undervalued.

Key valuation signals for OSSFF:

  • Additional Paid-In Capital: $85.5 Mil
  • GF Value™: $5.26 vs. price of $4.53 (14% below fair value)
  • GF Score™: 87/100

No single metric tells the full story. See the OSSFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Embla Medical hf Business Description

Address Grjothals 5, Reykjavik, ISL
Embla Medical hf operates as an orthopedic products company specializing in the design, development, manufacturing and sales of prosthetics and bracing & supports products. The company also provides patient care through a network of Orthotic and Prosthetic (O&P) facilities. It sells its products in multiple countries, with Europe and North America representing its principal markets. The company operates within three business segments: Prosthetics & Neuro Orthotics, Bracing & Supports and Patient Care. The majority of the company's revenue is derived from the Prosthetics & Neuro Orthotics, which includes products designed for users with varying mobility needs, ranging from lower-activity applications to solutions intended for more active use.
87GF Score

Get the complete analysis for OSSFF

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.53
Price
$5.26
GF Value